Background. Peritoneal adhesions are a common complication after abdominal surgery. They cause small bowel obstruction, female infertility and chronic abdominal pain. Peritoneal adhesions also hamper uniform drug distribution in the peritoneal cavity, thereby reducing the efficacy of intraperitoneal chemotherapy after cytoreductive surgery. 
Introduction
Peritoneal adhesions are defined as pathological attachments between tissues and organs, usually between the omentum, bowel loops and the abdominal wall. They can be classified as congenital or acquired [1] - [3] . The majority of adhesions is acquired and can be subdivided according to their inflammatory or postsurgical etiology. Inflammatory adhesions result from the inflammatory response of the peritoneum during intra-abdominal inflammatory processes such as acute appendicitis, pelvic inflammatory disease and exposure to intestinal contents [1] - [3] . Postsurgical adhesions develop when injured tissue fuse together to form scar tissue [1] - [4] . The reported incidence of intraperitoneal (IP) adhesions varies from 67 to 93% after general intra-abdominal surgery and up to 97% after open gynaecologic surgery [1] - [3] , [5] . Peritoneal adhesions affect quality of life by causing small bowel obstruction, female infertility, chronic abdominal pain and inadvertent organ injury after reoperative surgery [1] - [7] .
Severe peritoneal adhesions are often observed after major surgery for abdominal malignancies.
Cytoreductive surgery followed by IP chemotherapy is becoming the standard of care for patients with advanced cancers such as colorectal or ovarian tumours. Peritoneal carcinomatosis results from dissemination of primary intra-abdominal and gynecological cancers [8] - [14] . The effectiveness of IP chemotherapy depends on uniform drug distribution in the peritoneal cavity as well as on the concentration and exposure time of residual tumours to the instilled drugs. Adhesions occuring after cytoreductive surgery can compromise the effect of IP chemotherapy [15] - [17] . Therefore, a formulation that distributes evenly in the abdominal cavity, prevents peritoneal adhesions and simultaneously extends residence time and enhances local drug concentration is of high clinical interest. Biocompatible microspheres might be suitable candidates to meet these objectives.
Microparticles for IP drug delivery are promising since they can overcome some major challenges. They can distribute throughout the entire peritoneal cavity. Due to their size, they can remain in the peritoneal cavity and locally provide an extended release of a drug, such as a chemotherapeutic agent [16] , [18] - [21] . The size range of the microspheres is crucial as size determines the residence time in the peritoneal cavity. Small particles can be cleared from the peritoneal cavity into the lymphatic capillaries through openings in the diaphragm (stomata), or they can be absorbed through the peritoneal membrane. The stoma openings are 3-12 µm in diameter and provide a direct access to the underlying submesothelial lymphatic system, allowing rapid removal of cells, fluid, bacteria and particles from the peritoneal cavity. Particles with a larger diameter are longer retained in the peritoneal cavity. Particle size will also affect drug release rate as smaller particles release the drug faster, due to their higher surface area-to-volume ratio. Furthermore, particle size will affect the spatial distribution in the abdominal cavity. Previous studies show that smaller microparticles are evenly distributed throughout the abdominal cavity whereas larger microparticles are mainly localized in the lower abdomen [16] , [18] , [20] , [22] - [25] .
Microspheres for IP use should not cause an inflammatory reaction, nor should they have an intrinsic tendency to create peritoneal adhesions. Inflammation is dependent on the type of material and the particle size [15] , [24] . The use of biocompatible and biodegradable polymers such as gelatine and collagen might overcome toxicity and biodegradability problems, which are related to the use of synthetic materials [26] .
Gelatin is an ideal candidate to formulate biocompatible microspheres. It has excellent film-and particle-forming capacities, as well as bioadhesive properties. Gelatin is not toxic or carcinogenic, and it is a readily available and inexpensive material. As a result, gelatin has been extensively used for medical, pharmaceutical and cosmetic applications [26] - [30] . However, its rapid dissolution in an aqueous environment under in vivo conditions requires the use of crosslinkers for long-term biomedical application of gelatin microspheres [26] , [27] , [29] , [30] .
The selection of a chemical crosslinking agent is critical since residual crosslinking agent in the formulation can cause toxic side effects. Numerous chemical reagents have been used including glutaraldehyde, formaldehyde, diepoxide and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide [28] , [30] - [32] . Genipin, a naturally occurring crosslinker, isolated from the fruits of the plant Gardenia jasminoides, is superior to other chemical crosslinking agents as it is 10 000 times less toxic than aldehyde and epoxy crosslinkers. Furthermore, genipin improves both thermal and structural stability of crosslinked gelatin since the degradation rate of genipin-crosslinked gelatin microspheres was significantly slower compared to aldehyde as crosslinker. Therefore, genipin is a promising crosslinking agent to formulate a long-acting biomedical implant [27] , [32] - [35] . This study presents the formulation and in vitro and in vivo characterization of genipincrosslinked gelatin microspheres. The aim of this study is to develop a formulation that evenly distributes in the peritoneal cavity. The potential efficacy of genipin-crosslinked gelatin microspheres to prevent postsurgical peritoneal adhesions is evaluated in a standardised mouse model [17] .
Materials and methods

Formulation of gelatin microspheres
Gelatin microspheres were prepared by a modified emulsification solvent extraction method as reported by Adhirajan et al. (2007) [28] . 10 ml of a gelatin (Gelatin Type B, Rousselot, Ghent, Belgium) aqueous solution was added dropwise at 60°C to 100 ml of peanut oil (Fagron, Waregem, Belgium) pre- at 900 rpm using a magnetic stirrer. The emulsion was then rapidly cooled to 5°C in an ice bath and stirring continued for 20 minutes to allow the spontaneous gelation of the gelatin aqueous solution. The microspheres were dehydrated by the addition of 150 ml precooled acetone (Sigma-Aldrich) and stirring was continued for 30 minutes. The microspheres were collected by filtration using a cellulose filter (Whatman filter grade 4) and a vacuum pump. The microspheres were washed several times with acetone to remove residual oil from their surface. The washed microspheres were finally vacuum-dried at room temperature for at least 2 days.
Crosslinking of gelatin microspheres
Gelatin microspheres were crosslinked using various genipin (Wako Chemicals, Neuss, Germany) concentrations and crosslinking times [33] . The prepared gelatin microspheres (500 mg) were dispersed in 10 ml 90% v/v ethanol (Sigma-Aldrich) solution containing different genipin concentrations (0.1, 0.5 and 1% w/v) and stirred at room temperature using a magnetic stirring for different time periods (5, 15, 24, 48, 72, 96 h) . At the end of incubation, the genipin solution was aspirated and the crosslinked gelatin microspheres were rinsed with 15 ml aqueous ethanol solution (99.5% v/v) for 4 hours to remove residual genipin. Subsequently, the rinsed microspheres were filtered from the ethanol solution and vacuum-dried at room temperature for 24 h to remove ethanol.
Characterization of microspheres
The morphology of gelatin microspheres in dispersed state was examined by optical microscopy (Leica DM2500 P).
Particle size and size distribution of the microspheres dispersed in water were measured in triplicate by laser diffraction analysis using a 
Evaluation of the degree of crosslinking
A ninhydrin assay was performed to determine the degree of crosslinking by comparing the percentage of free amino groups in genipin-crosslinked gelatin microspheres and uncrosslinked gelatin microspheres [29] , [35] . The ninhydrin reagent consisted of two solutions. Solution A contained 1.05 g citric acid (Fagron), 0.4 g NaOH (Sigma-Aldrich) and 0.04 g SnCl.H 2 O (Sigma-Aldrich) dissolved in 25.0 ml water. Solution B was made by mixing 1.0 g ninhydrin (Sigma-Aldrich) with 25.0 ml ethylene glycol monomethyl ether (Fisher Scientific, Erembodegem, Belgium). Solutions A and B were combined and stirred for 45 min in the dark at room temperature. Solutions of known concentrations of glycine (SigmaAldrich) were prepared to generate a standard curve. Uncrosslinked and crosslinked microspheres were lyophilized prior to analysis. Samples of 3 mg lyophilized microspheres were weighed and rehydrated in 100 µL water. 1.0 ml ninhydrin solution was added to the samples and standard solutions, followed by incubation at 100°C for 20 min in the dark. Next, the samples were cooled to room temperature and 5.0 ml 50% isopropanol (Fisher Scientific) was added to each sample. The optical absorbance of the solutions at 570 nm was recorded with a spectrophotometer (UV-1650PC, Shimadzu Benelux, Antwerp, Belgium). The amount of free amino groups in the sample, after heating with ninhydrin, is proportional to the optical absorbance of the solution. The concentration of free NH 2 groups in the sample is determined from a standard curve of glycine concentration versus absorbance. 
Evaluation of in vitro degradation
An in vitro enzymatic degradation test was carried out using collagenase [27] , [28] , [32] . (Sigma-Adrich) and 25 mM EDTA (Fagron) in water) was added to prevent further degradation.
Ninhydrin assay was performed to quantify the percentage of degradation [36] . 2 ml of ninhydrin solution, prepared as described in section 2.5, was added to the samples. The reaction was carried out at 100°C for 10 minutes in the dark. Samples were cooled to room temperature and 2 ml 50% v/v isopropanol (Fisher Scientific) was added. Optical absorbance of the solutions was measured at 570 nm using a spectrophotometer (UV-1650PC, Shimadzu Benelux, Antwerp, Belgium). The absorbance at 570 nm was proportional to the amount of degradation. An increase in degradation resulted in more free amino acids and therefore higher absorbance. Percentage of degradation was compared to degradation of noncrosslinked gelatin microspheres.
A hydrolytic degradation study was performed by dispersing uncrosslinked and genipincrosslinked gelatin microspheres (GP-MS) in 5 ml phosphate buffered saline (PBS) and incubated at 37°C for the duration of the study. The morphology of the microspheres was daily observed using optical microscopy (Leica DM2500 P) [37] .
In vitro cell viability
The human ovarian carcinoma cell line (SKOV-3, obtained from the American Type Culture Collection) was cultured at 37°C in a 5% CO 2 -containing humidified atmosphere in McCoys medium (Invitrogen, Merelbeke, Belgium). Medium was supplemented with 10% fetal bovine serum, penicillin, streptomycin (Invitrogen) and fungizone (Bristol Myers Squibb, Braine-l'Alleud, Belgium).
To test the cytotoxicity of the crosslinker a broad range of genipin concentrations was evaluated 
Animal study
All animal experiments were approved by the Ethical Committee of the Faculty of Medicine, Ghent University (ECD 14/11). Female Balb/c mice (Envigo, Horst, The Netherlands) were kept in standard housing conditions with water and food ad libitum and a 12 hours light/dark cycle.
In vivo biocompatibility, degradability and toxicity study
15 Balb/c mice, aged 6 weeks, received an IP injection of the formulation into the left lower quadrant. GP-MS were sterilised in ethanol solution prior to administration. 50 mg sterilised gelatin microspheres, crosslinked using 0.5% w/v genipin for 48 h, were suspended in 2 ml sterile physiological saline (Baxter, Lessines, Belgium) and injected. All animals were observed after administration of the formulation, including general condition (activity, energy, hair, faeces, behaviour pattern and other clinical signs), body weight and mortality. After 2, 7, 14, 21 and 28 days three mice per time point were sacrificed by cervical dislocation under anaesthesia with sevoflurane (Sevorane ® , Abbott, Waver, Belgium). A vertical incision along the midline through the abdominal wall muscle and peritoneum was made and the abdominal cavity was exposed. Distribution, compatibility and degradability of GP-MS were examined. The abdominal cavity was photographed. Specimens of cecum, colon, greater omentum and parietal peritoneum were assigned for histopathological examination to evaluate local tolerance.
Specimens of spleen, pancreas, liver and kidneys were taken to evaluate general toxicity. Tissues were fixed immediately by immersion in 4% paraformaldehyde in PBS for 72 hours and embedded in paraffin.
The tissues were then sectioned, stained with hematoxylin and eosin (H&E). All slides were examined for tissue inflammatory reaction by a pathologist in a blinded manner. Peritoneal adhesions were induced by the abdominal wall and cecum abrasion peritoneal adhesion model as previously reported [17] , [38] , [39] . An anterior midline incision was made through the abdominal wall and peritoneum. The cecum was identified and abraded until visible damage by scrubbing with sterile dry surgical gauze. The damaged cecum was returned to the abdominal cavity and a 1x1 cm apposing parietal peritoneal wall defect was created using a sterile dry gauze. were checked daily for changes in behaviour (feeding, grooming, etc.) and body weight was monitored.
Effectiveness of gelatin microspheres in prevention of postoperative peritoneal adhesions
The anti-adhesion efficacy of GP-MS was evaluated 2, 7 and 14 days post-operative, 3 GP-MStreated mice and 1 control mouse per time point. Mice were sacrificed by cervical dislocation under anaesthesia with sevoflurane. Abdominal cavity was exposed and tissues were investigated on typical inflammatory signs. Adhesions were qualified and quantified using standard scoring systems. The qualitative adhesion scoring (Table 1) was based on extent, type and tenacity of adhesions, as described by [40] , [41] with some modifications.
The extent of adhesion was assessed by the area of the peritoneal cavity that was covered by adhesions. Therefore, the abdominal cavity was hypothetically subdivided into 8 sections, each consisting 12.5% of abdominal area, as illustrated in Figure 1 [41], [42] .
Adhesions were assessed according to the quantitative scoring system reported in Egea et al.
(1995) with some modifications [42] as displayed in Table 2 .
Specimens for histopathological examination were taken from the cecum, abdominal wall and, if applicable, adhesion tissue. The tissues were fixed immediately by immersion in 4%
paraformaldehyde in PBS for 72 h and embedded in paraffin. The tissues were then serially sectioned, stained with H&E and analyzed using light microscopy by a pathologist in a blinded manner. was applied in a thin layer to the lateral and ventral surface of the damaged cecum and the 1x1 cm parietal peritoneal defect before closure of the abdomen according to the manufacturer's instructions.
All proceedings were performed under clean conditions by one surgeon in a blinded way. Mice were monitored for recovery from anesthesia and their general conditions and body weight were followed daily.
At day 14 a second ventral laparotomy was performed, the abdominal cavity was exposed and tissues were investigated on typical inflammatory signs. In addition, adhesions were qualified and quantified in a blinded manner using three scoring systems. Qualitative adhesion scoring was based on extent, type and tenacity of adhesions, as described by with some modifications [40] , [41] as displayed in Table 1 . Adhesions were assessed according to the quantitative scoring system reported in Egea et al. (1995) with some modifications [41] , [42] as displayed in Table 2 . Additionally, adhesions were graded (Table 3) according to the Zühlke grading classification [41] , [43] .
paraformaldehyde in PBS for 72 h and embedded in paraffin. The tissues were then serially sectioned, stained with H&E and analyzed using light microscopy by a pathologist in a blinded manner.
Blood samples were obtained from the tail vein of mice prior to induction of adhesions, at day 1 and 7 postoperative. At day 14 blood was obtained by intracardiac puncture using a 27 G needle and mice were sacrificed by cervical dislocation under anesthesia sevoflurane. The blood samples were centrifuged at 2500 rpm during 10 minutes. Additionally, peritoneal lavages were performed at day 0, 1, 7 and 14. Five ml of cooled PBS was intraperitoneally injected, abdomen was gently massaged and peritoneal fluid was collected. Quantification of cytokines interleukin (IL) 1ß, IL-6 and TNF- in plasma and peritoneal fluid was performed using ELISA kits (Qiagen, Antwerp, Belgium).
Statistical analysis were performed using the nonparametric Wilcoxon-Mann Whitney test in GraphPad Prism™ version 5.2 to compare the total adhesion score, grade and extent of adhesion between each pair of treatment groups. The incidence of adhesions was compared using the Fisher's Exact test. A P-value < 0.05 on a two-tailed test was considered to be statistically significant.
Results and discussion
Formulation of gelatin microspheres
The size of gelatin microspheres can be controlled by adjusting the concentration of gelatin in the aqueous phase. A higher gelatin concentration increases the size of the aqueous droplets in emulsion and thus the size of the final gelatin microspheres. Nevertheless, a minimum viscosity is necessary for a good emulsification process as no microspheres or microspheres with a poor morphology were formed when an aqueous gelatin solution of 5 and 10 w/v % was used. A gelatin with a high gel strength (i.e.
bloom value of 265) was selected as this gelatin grade yielded microspheres with a better spherical morphology in comparison to gelatin grades with bloom values of 160, 200 and 250. Microspheres were not formed when a gelatin grade of 75 and 100 bloom was used. Aggregation tendency of the microspheres depended on the bloom value of gelatin: less aggregation was observed at higher bloom value. Addition of surfactants also controls the size of microspheres by reducing the size and the aggregation tendency of the gelatin droplets during the emulsification process [26] . 
Crosslinking of gelatin microspheres
Gelatin microspheres were crosslinked using genipin in various concentrations and crosslinking times. Blue coloration increased with higher genipin concentration and a longer incubation time:
ninhydrin assay confirmed that a higher degree of crosslinking is obtained when increasing genipin concentration and crosslinking time ( Figure 3 ).
Genipin can react with the free amino groups of lysine, hydroxylysine and arginine residues in proteins to form intra-and intermolecular crosslinks. The reaction between a genipin and an amino acid in gelatin is initiated by a nucleophilic attack of the amino group on the third carbon of genipin. The genipin ring is opened and an aldehyde group is formed. The resulting aldehyde group is attacked by the attached secondary amine group. Further radical reaction leads to dimerization. Hence, genipin may link peptide chains by introducing a dimeric genipin spacer with a cyclic structure. Consequently, genipin can form intramolecular crosslinks within a gelatin molecule and short-range intermolecular crosslinks between two adjacent gelatin molecules [27] , [29] , [44] . Intermediates formed during the crosslinking reaction are linked to the blue coloration. Some suggest that genipocyanin is a major component, a result of a 1:1 reaction between genipin and amino acid. Spontaneous reaction of genipin as azaphilone with an amino group forms a nitrogen-iridoid which undergoes dehydration to form an aromatic monomer [45] . Others speculate that genipin molecules may be polymerized before crosslinking with amino groups [31] .
Crosslinking gelatin microspheres did not induce changes in morphology or size. Photographs of GP-MS in the dispersed state are displayed in Figure 4 . Microspheres crosslinked during 5 h and 24
h had a mean volume diameter of 57.11 ± 5.03 µm (n=3) and 55.53 ± 5.08 µm (n=3), respectively.
In vitro degradation
The degradation mechanism of the microspheres is probably a combination of hydrolysis and proteolysis. Therefore, two types of degradation assays were performed. Proteolysis can be accelerated in case of metastasis as it has been noticed that tumour cell invasion and metastasis are related to a higher expression of degrading enzymes, such as heparanase, serine protease, thiol protease and metal- Collagenase I is secreted by both normal cells, eg. stromal fibroblasts, macrophages, endothelial and epithelial cells, as well as by tumour cells [46] - [49] . The in vitro proteolytic study allowed a rapid evaluation of the biodegradability. Enzymatic degradation properties of microspheres are displayed in Figure 5 . All microspheres were degraded within 48 hours. An increase in degree of crosslinking and genipin concentration resulted in a longer resistance to enzymatic degradation.
The resistance of GP-MS to hydrolysis was evaluated (Table 5) The degree of crosslinking allowed to tailor the degradation rate of microspheres and thus their residence time.
In vitro cell viability
Previous reports describe low cytotoxicity of genipin as crosslinking agent in comparison to aldehyde crosslinkers [27] , [32] - [35] . This study evaluated the influence of genipin on cell viability of SKOV-3 cells. Both concentration-and time-dependent influence of the crosslinking process on cell viability are evaluated since the gelatin microspheres are intended to be retained for a prolonged period in the peritoneal cavity ( Figure 6A ).
MTT assays clearly indicated that genipin influenced cell viability at high concentrations.
Concentrations of 0.5 w/v % and higher caused a steep decrease of cell viability after one day of incubation. Cell viability decreased further in time to a minimum of 20%. Acute cytotoxicity was noticed with a minimum cell viability of 25% after 48 h of exposure to 0.5 w/v % genipin. Surprisingly, cells seemed to recover in time which could reflect the loss of cell-cell contacts and mitochondrial reactivation [50] , [51] . the aforementioned cytotoxicity data, it is hypothesised that the free genipin released from the microspheres will not affect cell viability. The low amount of genipin released from the crosslinked microspheres is linked to the stable nature of the inter-and intramolecular crosslink [27] , [31] , [44] .
This hypothesis was confirmed by performing a new set of MTT assays where SKOV-3 cells were exposed to several concentrations of GP-MS with a degree of crosslinking of 60%. Figure 6B indicates that cell viability was not affected by the presence of GP-MS. Neither exposure time nor concentration of GP-MS had an influence on cell viability.
Animal study
In vivo distribution pattern, biocompatibility and degradability
Animals were followed during the entire period of the study and all of them tolerated the formulation well. Body weight gain was not different from the standard body weight increase and general activity was normal. The formulation consisted of GP-MS with a 60% degree of crosslinking using 0.5 w/v % genipin as crosslinking concentration. A high degree of crosslinking was chosen to ensure a long retention time in the peritoneal cavity in order to obtain information on the short and longer term inflammatory and toxicity responses.
The distribution of GP-MS in the abdominal cavity was visually evaluated (Figure 7 ) based on the blue colour of the particles. The microspheres displayed a distribution pattern similar to the flow of peritoneal fluid. The gelatin microspheres distribute throughout the whole abdominal cavity, from injection site to colon, cecum, omentum, diaphragm and liver, and accumulation of the formulation at the typical sites of peritoneal carcinomatosis was seen. The peritoneal carcinomatosis pattern has been described and tumour growth was predominantly found in the following locations: in the small pelvis, at the end of the ileal mesentery, at the sigmoid colon, and at the right paracolic gutter (cecum, ascending colon) [52] , [53] . Thus, the distribution pattern of the microspheres is an attractive characteristic in view of its intended use for drug delivery in the treatment of peritoneal carcinomatosis. Upon examination of the abdominal cavity and organs there were no visible signs of inflammation or intolerance caused by the presence of the formulation. Previous studies showed that biodegradable poly-(lactic-co-glycolic)
acid microspheres with a size range of 5 to 250 µm caused peritoneal adhesions and chronic inflammation after IP injection whilst nanoparticles caused fewer adhesions but were rapidly cleared from peritoneal cavity [24] . All tissues had a normal, healthy appearance and there were no adhesions observed after IP injection of GP-MS. Histopathological examination of the tissues confirmed that there were no signs of inflammation nor intolerance (Suppl. Figure 1a and 1b) . No abnormalities were observed in colon, cecum, greater omentum, parietal peritoneum and spleen, liver, pancreas or kidneys compared with the control group. To our knowledge, microspheres for IP administration that do not cause inflammation or intolerance have not yet been described. Nanoparticles are mainly used to achieve these requirements [24] , [54] , [55] . Since they suffer from rapid clearance, incorporation of nanoparticles into hydrogels has been reported [54] .
The formulation remained intact in the peritoneal cavity at day 2, 7, 14 and 21. A gradual decrease of the amount of microspheres over time was noticed, indicating the biodegradation of the formulation. At day 28, only a small amount of microspheres was still present in the abdominal cavity.
Effectiveness in prevention of postoperative peritoneal adhesions
Adhesions were induced by the abdominal wall and cecum abrasion peritoneal adhesion model as has described extensively [6] , [17] , [38] , [56] , [57] . The model is highly reproducible and adhesion formation can be easily scored. However, this model might not entirely relate to the clinical appearance of peritoneal adhesions after an abdominal operation, where adhesions are found spread throughout the peritoneal cavity and in between intestines. Nonetheless, the model provides a good indication of the effectiveness of the formulation and allows follow-up of the healing of peritoneum and cecum. GP-MS crosslinked using 0.5 w/v% genipin during 24 h were chosen as formulation to prevent peritoneal adhesions since a degree of crosslinking of 40% ensures complete degradation of the GP-MS within 14 days. Microspheres of 50 µm were chosen for in vivo studies since pilot studies using particles of 50, 100, 200 and 300 µm showed that the larger the particles, the more difficult to inject and particles were more evenly distributed in the peritoneal cavity using a smaller particle size.
Influence of GP-MS to the mechanism of adhesion formation over time
Scoring of adhesions was conducted 2,7 and 14 days after the induction of adhesions (Table 6 ).
All control mice (Figure 8 ) developed peritoneal adhesions. Cecum was attached to peritoneal wall (parietal adhesions) and dense adhesions were seen between colon-cecum and small intestines-cecum (visceral adhesions). Sharp dissection was required to separate the adhesions. At day 14, adhesions were vascularised. It is accepted that peritoneal remesothelization is completed by day 8 after peritoneal injury, thus formed adhesions will remain and vascularisation is initiated. Whilst peritoneal adhesions were formed in all control mice, none of the mice treated with GP-MS developed adhesions (Figure 9 ).
At day 2, the formulation was evenly distributed throughout the peritoneal cavity. The microspheres mass that remains, results in the organization and formation of adhesions [1] , [2] .
The balance between deposition and degradation of fibrin will determine normal peritoneal healing or adhesion formation. Fibrinolytic activity usually begins three days after peritoneal injury and increases to a maximum by day 8. Therefore, peritoneal adhesions will remain when remesothelialization is completed by day 8. Normal peritoneum has a high fibrolytic activity to prevent adhesion formation. But at sites of surgical or inflammatory injury, levels of PAI are increased, which inhibit fibrinolytic activity. Additionally, deficient blood supply and reduced tissue oxygenation, typically for surgical injury, decrease fibrinolysis resulting in adhesion development [1] , [2] .
Three time points (day 2, 7 and 14) were chosen to evaluate the complete cascade of peritoneal adhesion formation.
The microspheres were able to form a barrier between the injured peritoneal surfaces of cecum and parietal peritoneum, thereby hindering the formation of fibrin strands during the remesotheliazation phase. At day 14, when peritoneal healing is completed, adhesions will remain [1] , [2] . GP-MS-treated mice did not develop peritoneal adhesions and the peritoneal layer covering abdominal wall and viscera had a normal appearance by day 14. In contrast, control mice developed peritoneal adhesions which were vascularised by day 14 since there was no IP barrier present.
Histopathological analysis of cecum, peritoneum and adhesion tissue allowed to further evaluate the differences in formation of peritoneal adhesions in time between control and GP-MS-treated mice.
Tissue samples of control mice clearly showed inflammation. Two days after induction of peritoneal adhesions (Suppl. No infiltration into muscle tissue of abdominal wall was seen.
Fourteen days after induction of peritoneal adhesions (Suppl. Figure 2c) , adipose tissue associated with cecum of control mice, i.e. adhesion tissue, showed a severe inflammatory infiltrate.
Cecal mucosa displayed normal architecture whereas serositis was observed. Peritoneal tissue still showed active inflammation after fourteen days. Inflammatory cells were observed in adipose, connective and muscle tissue. Chronic inflammation was seen upon observation of adhesion tissue.
Cecal mucosa and serosa of GP-MS-treated mice had a normal appearance without signs of inflammation. Peritoneal tissue of most mice was healed after abrasion, although in some cases, a few inflammatory cells were observed. None of the tissues showed penetration of inflammatory cells into abdominal wall muscle tissue. Thus, histopathological examination showed that inflammatory reaction of cecum and peritoneum decreased over time. Cecum and peritoneum recovered and displayed normal histological appearance. Quantification of inflammatory markers, cytokines in plasma and peritoneal fluid, is performed in the proof-of-concept study detailed below. This permits confirmation of the hypothesis that GP-MS are able to reduce formation of peritoneal adhesions and allow healing of peritoneal wounds.
Proof of concept: effectiveness of GP-MS in the prevention of postsurgical peritoneal adhesions in a standardized mouse model
All animals had a healthy appearance and their general activity was normal. Furthermore, they gained body weight after the surgical procedure. Adhesions were seen in all control mice and animals of the comparison group (Hyalobarrier ® ). In the intervention group (GP-MS treated mice) 36% of the mice developed at least one adhesion, which represented a statistic significant reduction of 64% in incidence compared to the control group (P=0.0039; Fisher's Exact). The high incidence (100%) of adhesions noticed in the control group indicates that the standardized adhesion model is adequate to evaluate the effectiveness of agents in the prevention of postsurgical peritoneal adhesions.
The results of the quantitative scoring of the peritoneal adhesions are displayed in Table 7 .
Visceral adhesions were seen in all animals of the control ( Figure 10A ) and Hyalobarrier ® group ( Figure   10D ), compared to 18% of GP-MS treated mice ( Figure 10F ). The mice predominantly developed intestine-intestine adhesions. Parietal adhesions were seen in 64% and 45% of mice in the control Results of the qualitative assessment of peritoneal adhesions are displayed in Table 8 . The total adhesion score of the control group was 7.90 ± 1.70 compared to 1.18 ± 1.78 in the GP-MS group. The difference in total score between both groups was statistically significant (P < 0.0001; Wilcoxon-Mann Whitney). In addition, the GP-MS group (1.18 ± 1.78) and Hyalobarrier Dense adhesions were observed in 82% and 91% of mice in the Hyalobarrier ® and control group, respectively, whereas only filmy adhesions were seen in the GP-MS group. Furthermore, adhesions of GP-MS treated mice were very localized (extent of 0.45 ± 0.69) and felt easily apart. The 4 GP-MStreated mice where adhesions were observed had only 1 or 2 filmy adhesions which did not lead to clinical relevant complication [58] . Extended adhesions where ± 70% of peritoneal cavity was involved, were observed in Hyalobarrier ® (extent of 3.00 ± 1.10) and control group (extent of 2.64 ± 0.47). The adhesions mainly required sharp dissection to separate and was not possible without damaging of viscera of intestines or peritoneum.
An overview of the evaluation of the adhesion grading according to the Zühkle classification is displayed in Table 9 . All control mice developed grade 3 (55%) or 4 (27%) peritoneal adhesions except for two (18%) mice, who had grade 2 adhesions. Hyalobarrier clinical practice [62] , the effectiveness of GP-MP was compared to Hyalobarrier was not selected since it is a liquid barrier instead of a solid device and thereby attempts to separate injured surfaces by hydroflotation [1] . Additionally, Adept ® shows a limited peritoneal retention, characteristic for liquid agents [4] . Despite several similarities between GP-MS and Hyalobarrier ® gel, there is one major difference between both treatments. The GP-MS are intraperitoneally injected after complete closure of the ventral incision without attempt to direct the formulation towards the traumatized areas whereas Hyalobarrier ® gel is applied directly in a thin layer at the assumed sites of adhesion and stays in place due to its viscous and sticky properties.
Other studies reported that Hyalobarrier ® was able to reduce adhesions. Binda et al. reported a significant reduction of adhesions in Balb/c mice, but the research methodology was different from this study since adhesions were laparoscopically induced by hypoxia and normoxia [59] , [63] , [64] . Efficacy of Hyalobarrier ® was investigated in a rat uterine horn model [65] , [66] . Subsequently, cytokines IL-1ß, IL-6 and TNF-, inflammatory markers released during the peritoneal adhesions cascade [1] , [2] , were analysed in plasma and peritoneal fluid. None of the cytokines were present in plasma above the limit of detection (55.2 pg/ml for IL-1ß, 58.8 pg/ml for IL 6, 30.5 pg/ml for TNF-) at any time point (day 1, 7 and 14 post-operative). Cytokine analysis of peritoneal fluid (Suppl. Figure 4 ) illustrated that concentration of IL-1ß, IL-6 and TNF- of control and
Hyalobarrier-treated mice were slightly higher than GP-MS-treated mice at any time point but without significant difference. Cytokines were most abundantly present at day 1 after abrasion of cecum and peritoneum. IL-1 and TNF- are produced by activated macrophages in peritoneal fluid and mainly important in the early phase of wound healing. Production of IL-6 is up-regulated by IL-1 and TNF-.
These cytokines interact with the fibrinolytic pathway and influence the remodeling of the extracellular matrix which may be responsible for formation of adhesions after peritoneal injury [67] . Concentration of cytokines after induction of adhesions was higher for all animals than before induction. It has been reported that surgical tissue trauma is followed by a cascade of inflammatory signaling and activation of epithelial, endothelial and inflammatory cells, platelets and fibroblasts [68] . Nevertheless, no significant difference could be appointed and concentrations of cytokines were around limit of detection. The local induction of adhesions could be an explanation for the limited increase of concentration of cytokines, while a more extensive and aggressive model of induction of peritoneal adhesions could possibly induce a higher increase of cytokines in peritoneal fluid.
Conclusion
Spheroid gelatin microspheres were prepared by a modified emulsification solvent extraction method. Microspheres were stabilized by crosslinking using genipin. GP-MS did not influence cell viability when analysed by MTT assays using SKOV-3 cells. In vivo studies in mice showed excellent biocompatibility, distribution and degradation characteristics of GP-MS. GP-MS appear to be a promising strategy to prevent postoperative peritoneal adhesions. GP-MS-treated mice developed significantly less postsurgical adhesions when compared to saline and Hyalobarrier ® -treated animals.
Future work will include the incorporation of a cytostatic agent into the microspheres. Drug release will be monitored in vitro and in vivo. In addition, the potential efficacy of the drug-loaded microspheres will be evaluated in a mouse model for peritoneal metastasis of ovarian origin. Figure 1: Hypothetic subdivision of the abdominal cavity [41] . Tables   Table 1: Qualitative adhesion scoring system [40] Category Score Extent -No adhesion -1-25% of the peritoneal cavity involved -26-50% of the peritoneal cavity involved -51-75% of the peritoneal cavity involved -76-100% of the peritoneal cavity involved 
Figures
